2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 991

Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides
Abstract Number: 992

Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
Abstract Number: 1051

Identification of Differential Chromatin Accessibility Using ATAC-seq in a Novel 3D Tissue Culture System of Systemic Sclerosis
Abstract Number: 1016

Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis
Abstract Number: 1972

Identification of Distinct Lipidomic Profiles in Synovial Membranes from Inflammatory Arthritis by Mass Spectrometry Imaging
Abstract Number: 1073

Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis
Abstract Number: 1290

Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy
Abstract Number: 573

Identification of Factors Associated with Magnetic Resonance Images Changes Suggestive of Axial Spondyloarthritis in the Axial Skeleton of Individuals < 45 Years – Evaluation of Data from a Large Community Study
Abstract Number: 889

Identification of Genetic Variants Associated with Erosive Hand Osteoarthritis Using Pedigrees from a State-Wide Population-Based Cohort
Abstract Number: 1342

Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis
Abstract Number: 958

Identification of IFN-γ-producing Effector B Cells in Humans: Their Relevance to the Pathogenesis of Systemic Lupus Erythematosus
Abstract Number: 2034

Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Abstract Number: 1928

Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Abstract Number: 1067

Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis
Abstract Number: 2747

Identification of Naturally Presented Peptides of the Autoantigen Topoisomerase-I Reveals a Common Pathogenic Mechanism in Patients with Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].